In the HypoCOMPaSS RCT, participants with type 1 diabetes and IAH were allocated to insulin pump therapy (continuous subcutaneous insulin infusion, CSII) or multiple daily insulin injections (MDI) for insulin delivery. The gene discussed is INS; the disease is type 1 diabetes mellitus.